TP53 and neoplasm: Recent advances, such as the development of ReACp53, a peptide targeting mutant p53 aggregation, have demonstrated potential in reversing the tumor-promoting effects of mutant p53 by restoring its suppressor functions, reactivating mitochondrial apoptotic pathways, and increasing the sensitivity of cancer cells to existing treatments.